ClinicalTrials.gg
CompletedNCT00127283FASTUpdated Jan 12, 2017

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

A Phase 3 interventional study of eptacog alfa (activated) in Acquired Bleeding Disorder and Intracerebral Haemorrhage, sponsored by Novo Nordisk A/S. Completed at 167 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-12.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
829
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing recombinant FVIIa in Cerebral Hemorrhage — 1 open to participants now, 2 under way, 2 of them phase 3. recombinant FVIIa · Cerebral Hemorrhage.

Enrollment
2nd of 11
829 · median 90
Started
2005
with 2 others
Phase 3
3 of 11
1 open now
Registered
1st of 11
by date
Lead sponsor
5 of 11
Novo Nordisk A/S

Among the 11 studies testing recombinant FVIIa in Cerebral Hemorrhage, this one is the 2nd largest by enrollment, is one of 3 that started in 2005, is one of 3 in phase 3, and was the 1st registered.

Cerebral Hemorrhage

457 studies on the registry are indexed under Cerebral Hemorrhage; 172 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

1 of the 11 studies testing recombinant FVIIa in Cerebral Hemorrhage is open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About recombinant FVIIa

recombinant FVIIa: first FDA approval 1999 (Novoseven, Novoseven Rt), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 113 Cerebral Hemorrhage studies recruiting now, 59 (52%) set no upper age limit and 9 (8%) stop at 75 or younger; 2 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing recombinant FVIIa in Cerebral Hemorrhage, or all of them as a file.
02

Study summary

This trial is conducted in Asia, Europe, Middle East, North America, Oceania, and South America.

The purpose of this study is to evaluate the treatment of Recombinant Factor VIIa (eptacog alfa (activated)) in patients with acute intracerebral bleeding. It is expected that more patients will recover without severe permanent disability after acute treatment with Recombinant Factor VIIa by reducing further intracerebral bleeding.

03

Conditions studied

  • Acquired Bleeding Disorder
  • Intracerebral Haemorrhage

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Spontaneous intracranial hemorrhage (ICH) within 3 hours after first symptom

Exclusion criteria

Exclusion Criteria:

  • Patients with secondary ICH
  • Pre-existing disability
  • Haemophilia
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
829 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Reducing disability and improving clinical outcome

    Time frame: After 3 months

Secondary outcomes

  1. Reducing mortality

  2. Reducing hematoma growth

07

Study locations

167 sites
  • Novo Nordisk Investigational Site
    Birmingham, Alabama 35209, United States
  • Novo Nordisk Investigational Site
    Mobile, Alabama 36617, United States
  • Novo Nordisk Investigational Site
    Phoenix, Arizona 85013, United States
  • Novo Nordisk Investigational Site
    Fort Smith, Arkansas 72901, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90024, United States
  • Novo Nordisk Investigational Site
    Oceanside, California 92056, United States
  • Novo Nordisk Investigational Site
    Orange, California 92868-4280, United States
  • Novo Nordisk Investigational Site
    Sacramento, California 95816, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92103, United States
  • Novo Nordisk Investigational Site
    San Francisco, California 94110-3594, United States
  • Novo Nordisk Investigational Site
    San Francisco, California 94143-0780, United States
  • Novo Nordisk Investigational Site
    Stanford, California 94305, United States
  • Novo Nordisk Investigational Site
    Denver, Colorado 80204, United States
  • Novo Nordisk Investigational Site
    Denver, Colorado 80262, United States
  • Novo Nordisk Investigational Site
    Englewood, Colorado 80113, United States
  • Novo Nordisk Investigational Site
    Hartford, Connecticut 06102, United States
  • Novo Nordisk Investigational Site
    Washington, District of Columbia 20010, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32209, United States
  • Novo Nordisk Investigational Site
    Melbourne, Florida 32901, United States
  • Novo Nordisk Investigational Site
    Tallahassee, Florida 32308, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33606, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30320, United States
  • Novo Nordisk Investigational Site
    Augusta, Georgia 30912-3260, United States
  • Novo Nordisk Investigational Site
    Decatur, Georgia 33033, United States
  • Novo Nordisk Investigational Site
    Honolulu, Hawaii 96813, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60611, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60612, United States
  • Novo Nordisk Investigational Site
    Maywood, Illinois 60153, United States
  • Novo Nordisk Investigational Site
    Peoria, Illinois 61637, United States
  • Novo Nordisk Investigational Site
    Fort Wayne, Indiana 46805, United States
  • Novo Nordisk Investigational Site
    Indianapolis, Indiana 46260, United States
  • Novo Nordisk Investigational Site
    Iowa City, Iowa 52242, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40536, United States
  • Novo Nordisk Investigational Site
    Louisville, Kentucky 40202, United States
  • Novo Nordisk Investigational Site
    Baltimore, Maryland 21287, United States
  • Novo Nordisk Investigational Site
    Boston, Massachusetts 02118, United States
  • Novo Nordisk Investigational Site
    Boston, Massachusetts 02144, United States
  • Novo Nordisk Investigational Site
    Boston, Massachusetts 02215, United States
  • Novo Nordisk Investigational Site
    Detroit, Michigan 48201, United States
  • Novo Nordisk Investigational Site
    Golden Valley, Minnesota 55422, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Mississippi 39216, United States
  • Novo Nordisk Investigational Site
    Kansas City, Missouri 64111, United States
  • Novo Nordisk Investigational Site
    St. Louis, Missouri 63110-1010, United States
  • Novo Nordisk Investigational Site
    St. Louis, Missouri 63110, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89109, United States
  • Novo Nordisk Investigational Site
    Lebanon, New Hampshire 03756-0001, United States
  • Novo Nordisk Investigational Site
    Cherry Hill, New Jersey 08034, United States
  • Novo Nordisk Investigational Site
    Hackensack, New Jersey 07465, United States
  • Novo Nordisk Investigational Site
    Ridgewood, New Jersey 07450, United States
  • Novo Nordisk Investigational Site
    Buffalo, New York 14215, United States
  • Novo Nordisk Investigational Site
    New York, New York 10032, United States
  • Novo Nordisk Investigational Site
    Stony Brook, New York 11794-8121, United States
  • Novo Nordisk Investigational Site
    Chapel Hill, North Carolina 27599-7025, United States
  • Novo Nordisk Investigational Site
    Charlotte, North Carolina 28232-2861, United States
  • Novo Nordisk Investigational Site
    Durham, North Carolina 27705, United States
  • Novo Nordisk Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • Novo Nordisk Investigational Site
    Cincinnati, Ohio 45267, United States
  • Novo Nordisk Investigational Site
    Cleveland, Ohio 44195, United States
  • Novo Nordisk Investigational Site
    Portland, Oregon 97225, United States
  • Novo Nordisk Investigational Site
    Portland, Oregon 97239, United States
  • Novo Nordisk Investigational Site
    Allentown, Pennsylvania 18103-6208, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • Novo Nordisk Investigational Site
    Pittsburgh, Pennsylvania 15212-4746, United States
  • Novo Nordisk Investigational Site
    Pittsburgh, Pennsylvania 15213-2546, United States
  • Novo Nordisk Investigational Site
    Charleston, South Carolina 29425, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37403, United States
  • Novo Nordisk Investigational Site
    Hashville, Tennessee 37232, United States
  • Novo Nordisk Investigational Site
    Memphis, Tennessee 38163, United States
  • Novo Nordisk Investigational Site
    Nashville, Tennessee 37205, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75390-8897, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77030, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78229, United States
  • Novo Nordisk Investigational Site
    Burlington, Vermont 05401, United States
  • Novo Nordisk Investigational Site
    Charlottesville, Virginia 22908, United States
  • Novo Nordisk Investigational Site
    Seattle, Washington 98102, United States
  • Novo Nordisk Investigational Site
    Madison, Wisconsin 53792-3236, United States
  • Novo Nordisk Investigational Site
    Parkville, Victoria 3052, Australia
  • Novo Nordisk Investigational Site
    Camperdown, 2050, Australia
  • Novo Nordisk Investigational Site
    Gosford, 2250, Australia
  • Novo Nordisk Investigational Site
    Heidelberg Heights, 3081, Australia
  • Novo Nordisk Investigational Site
    Graz, 8036, Austria
  • Novo Nordisk Investigational Site
    Innsbruck, 6020, Austria
  • Novo Nordisk Investigational Site
    Antwerpen, 2020, Belgium
  • Novo Nordisk Investigational Site
    Brugge, 8000, Belgium
  • Novo Nordisk Investigational Site
    Brussels, 1070, Belgium
  • Novo Nordisk Investigational Site
    Brussels, 1200, Belgium
  • Novo Nordisk Investigational Site
    Sao Cristóvao, 20941-150, Brazil
  • Novo Nordisk Investigational Site
    Vila Clementino, 04039-032, Brazil
  • Novo Nordisk Investigational Site
    Edmonton, Alberta T6G 2B7, Canada
  • Novo Nordisk Investigational Site
    Halifax, Nova Scotia B3H 3A7, Canada
  • Novo Nordisk Investigational Site
    Calgary, T2N 2T9, Canada
  • Novo Nordisk Investigational Site
    Greenfield Park, J4V 2H1, Canada
  • Novo Nordisk Investigational Site
    London, N6A 5A5, Canada
  • Novo Nordisk Investigational Site
    Mississauga, L5B 1B8, Canada
  • Novo Nordisk Investigational Site
    Montreal, H2L 4M1, Canada
  • Novo Nordisk Investigational Site
    Montreal, H3A 2B4, Canada
  • Novo Nordisk Investigational Site
    Ottawa, KIH 8L6, Canada
  • Novo Nordisk Investigational Site
    Quebec, G1J 1Z4, Canada
  • Novo Nordisk Investigational Site
    Saint John, E2L 4L2, Canada

Showing the first 100 of 167 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Hsia CC, Chin-Yee IH, McAlister VC. Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Ann Surg. 2008 Jul;248(1):61-8. doi: 10.1097/SLA.0b013e318176c4ec. PubMed 18580208 ↗
  • Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T; FAST Trial Investigators. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008 May 15;358(20):2127-37. doi: 10.1056/NEJMoa0707534. PubMed 18480205 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2005, a primary completion of Jan 2007 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2005
First posted
Aug 5, 2005
Start
May 2005
Primary completionActual
Jan 2007
CompletionActual
Jan 2007
Last update
Jan 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00127283
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 5, 2005
Start date
May 2005
Primary completion
Jan 2007
Completion
Jan 2007
Last update
Jan 12, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant FVIIa

Start the discussion